期刊文献+

VEGI基因转移抑制角膜新生血管的实验研究(英文) 被引量:4

Inhibition of corneal neovascularization by vascular endothelia growth inhibitor gene
下载PDF
导出
摘要 目的:探讨以阳离子脂质体介导重组人VEGI基因转移对角膜新生血管(corneal neovascularization,CNV)的抑制作用。方法:角膜缝线法制作兔CNV模型,用结膜下注射的方法将阳离子脂质体包裹的VEGI重组质粒(pcDNA4-VEGI)转染入兔角膜,裂隙灯显微镜下观察记录各组兔CNV长出的时间、长度和数量,并分别于基因转染后3,7,14及21d以免疫组织化学方法观察VEGI基因表达情况,观察其对CNV的抑制作用。结果:基因转染组CNV平均出现时间为6.3d,对照组分别为3.1,3.2,3.2d不等,差异有统计学意义(F=39.838,P<0.01);基因转染后3d,转染组实验兔未出现CNV,对照组已有部分兔眼出现CNV;转染后第7d,转染组实验兔的CNV纤细,累及钟点数局限于缝线周围,对照组兔的CNV最长为2.9mm,血管密集;转染后第14d,转染组兔CNV最长达4.0mm,对照组新生血管最长达6.4mm,累及钟点数为3.2个;各时间段基因转染组CNV长度、平均面积与对照组相比,差异均有统计学意义(q=17.386,P<0.01)。免疫组织化学显示角膜上皮、基质、新生血管管壁细胞的VEGI表达阳性。各实验指标与对照组比较,差异有统计学意义(均P<0.05)。结论:VEGI基因对CNV有抑制作用。 AIM:To evaluate the effect of EffecteneTM lipofectine mediated plasmids encoding human pcDNA4-vascular endothelia growth inhibitor(pcDNA4-VEGI) gene on corneal neovascularization(CNV).METHODS:Forty New Zealand albino rabbits were sutured by 5-0 silk on the superior cornea to induce CNV and divided into 4 random teams,ten per each team:team A:transfected by pcDNA4-VEGI gene mediated by EffecteneTM lipofectine transfection;team B:by plasmid pcDNA4;team C:by EffecteneTM,and team D:by normal saline.Length and area of CNV were observed under slit lamp every day after transfection.Immunohistochemistry was performed to detect the expression of VEGI protein in corneas at day 3,7,14 and 21.RESULTS:1) Average occurrence of CNV was 6.3 days in team A,3.1 days in team B,3.2 days in team C,and 3.2 days in team D.Difference was significant between A and other teams(P0.01);2) Length and average area of CNV in each period in team A was significantly different from those in team B,C and D(P0.01);3) VEGI expressions were observed in epithelium,stroma,endothelium and the cliff of CNV in team A at 3 days after transfection by immunohistochemical staining.None VEGI positive cells were found in the control teams(team B,C and D) all the time.CONCLUSION:EffecteneTM lipofectine transfection technique can effectively transfect pcDNA4-VEGI gene into rabbit cornea and the length and CNV areas can be inhibited by VEGI gene.
作者 王鸿 王冰
出处 《国际眼科杂志》 CAS 2011年第2期195-198,共4页 International Eye Science
基金 supported by Shandong Provincial Science Council Grant,China(No.2008BS03052)~~
关键词 角膜新生血管 VEGI基因 基因治疗 corneal neovascularization vascular endothelia growth inhibitor gene therapy
  • 相关文献

参考文献12

  • 1Dana MR,Streilein JW.Loss and restoration of immune privilege in eyes with corneal neovascularization.Invest Ophthalmol Vis Sci 1996;37(12):2485-2494.
  • 2Lee P,Wang CC,Adamis AP.Ocular neovascularization:an epidemiologic review.Surv Ophthalmol 1998;43(3):245-269.
  • 3Tan KB,Harrop J,Reddy M,Young P,Terrett J,Emery J,Moore G,Truneh A.Characterization of an novel TNF like ligand and recently described TNF ligand and TNF receptor super family genes and their constitutive and inducible expression in hematopoietic and non hematopoietic cells.Gene 1997;204(1-2):35-46.
  • 4Zhai Y,Yu J,Iruela-Arispe L,Huang WQ,Wang Z,Hayes AJ,Lu J,Jiang G,Rojas L,Lippman ME,Ni J,Yu GL,Li LY.Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI,anovel cytokine of the TNF superfamily.Int J Cancer 1999;82(1):131-136.
  • 5Yu J,Tian S,Metheny-Barlow L,Chew LJ,Hayes AJ,Pan H,Yu GL,Li LY.Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor.Circ Res 2001;89(12):1161-1167.
  • 6Epstein RJ,Stulting RD,Hendricks RL,Harris DM.Corneal neovascularization:pathogenesis and inhibition.Cornea 1987;6(4):250-257.
  • 7Romano G,Pacilio C,Giordano A.Gene transfer technology in therapy:current applications and future goals.Oncologist 1998;3(4):225-236.
  • 8Buning H,Braun-Falco M,Hallek M.Progress in the use of adeno-associated viral vectors for gene therapy.Cells Tissues Organs 2004;(177):139-150.
  • 9Milani JK,Pleyer U,Dukes A,Chou HJ,Lutz S,R ckert D,Schmidt KH,Mondino BJ.Prolongation of corneal allograft survival with liposome-enclosporine in the rat eye.Ophthalmology 1993;100(6):890-896.
  • 10Zhai Y,Ni J,Jiang GW,Lu J,Xing L,Lincoln C,Carter KC,Janat F,Kozak D,Xu S,Rojas L,Aggarwal BB,Ruben S,Li LY,Gentz R,Yu GL.VEGI,a novel cytokine of the tumor necrosis factor family,is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo.FASEB J 1999;13(1):181-189.

同被引文献33

  • 1陈胜,冯春燕,胡艳红,胡俊,黄苏萍,衡先培.糖尿病大鼠视网膜组织VCAM-1表达及祛瘀化痰中药干预的研究[J].福建中医药大学学报,2013,23(6):20-23. 被引量:3
  • 2谢立信,曹景,董晓光,杨雪萍.环孢霉素A和地塞米松局部应用对角膜移植免疫排斥的疗效观察[J].眼科研究,1995,13(1):24-26. 被引量:8
  • 3丁莉莉,魏锐利,蔡季平.VEGI和cyclo-VEGI抗眼部肿瘤的前景展望[J].眼科新进展,2007,27(3):226-228. 被引量:5
  • 4Rodrigues M, Xin X, Jee K, et al. VEGF secreted by hypoxic Mttller cells induces MMP- 2 expression and activity in endothelial cells to promote retinal neovascularization in proliferative diabetic retinopathy. Diabetes 2013 ;62 ( 11 ) : 3863-3873.
  • 5Chauvet S, Burk K, Mann F. Navigation rules for vessels and neurons : cooperative signaling between VEGF and neural guidance cues. Cell Mol Life Sci 2013 ;70 (10) : 1685-1703.
  • 6Duan L, Yang G, Zhang R, et al. Advancement in the research on vascular endothelial growth inhibitor (VEGI). Target Oncol 2012 ;7 (1) : 87 -90.
  • 7Zhang N, Sanders A J, Ye L, et al. Expression of vascular endothelial growth inhibitor (VEGI) in human urothelial cancer of the bladder and its effects on the adhesion and migration of bladder cancer cells in vitro. Anticancer Res 2010 ;30( 1 ) :87-95.
  • 8Chauhan VP, Stylianopoulos T, Martin JD, et al. Normalization of tuinour blood vessels improves the delivery of nanomedicines in a size- dependent manner. Nat Nanotechnol 2012 ;7 (6) : 383-388.
  • 9Liu Y, Costa MB,Gerhardinger C. IL-1t3 is upregulated in the diabetic retina and retinal vessels: cell-specific effect of high glucose and IL-113 autostimulation. PLoS One 2012 ;7 (5) : e36949.
  • 10Tolentino M. Systemic and ocular safety of intravitreal anti- VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011 ;56 (2) : 95-113.

引证文献4

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部